Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey
Background Therapeutic drug monitoring (TDM) may lead to more rational use of biologics. Still, TDM is largely underexplored in psoriasis. Little is known about the dosing behavior of biologics by dermatologists, and their attitude toward TDM. Objective Exploration of the awareness and need for the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-04-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2020.1832649 |
| _version_ | 1797683567824732160 |
|---|---|
| author | Lisa Schots Lynda Grine Rani Soenen Jo Lambert |
| author_facet | Lisa Schots Lynda Grine Rani Soenen Jo Lambert |
| author_sort | Lisa Schots |
| collection | DOAJ |
| description | Background Therapeutic drug monitoring (TDM) may lead to more rational use of biologics. Still, TDM is largely underexplored in psoriasis. Little is known about the dosing behavior of biologics by dermatologists, and their attitude toward TDM. Objective Exploration of the awareness and need for the concept of TDM in psoriasis amongst (inter)national dermatologists. Method A survey was distributed at the Belgian Dermatology Days 2019 and Skin Inflammation & Psoriasis International Network (SPIN) Congress 2019. Next, an online survey version was launched amongst the SPIN Scientific Committee members. We collected physician’s characteristics, prescription behavior of biologics, data regarding clinical response to biologics and attitude toward TDM. Results A total of 107 surveys were included for analysis. Most dermatologists were Belgium-based (54.2%), others from European (23.4%) or non-European countries (19.6%). Seventy percent performed either dose increase (64.8%), time interval shortening (74.6%), dose lowering (16.9%) or time interval extension (33.8%). The majority who performed dose adaptations acknowledged the need for TDM. Conclusion This study showed most dermatologists perform dose adaptations empirically. The need for TDM was indicated by the majority, implying the need for effective communication regarding availability, utility and implementation of TDM assays in daily dermatology practice. |
| first_indexed | 2024-03-12T00:16:14Z |
| format | Article |
| id | doaj.art-b474a90dfedc4c34a8396d2e573b23f9 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:16:14Z |
| publishDate | 2022-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-b474a90dfedc4c34a8396d2e573b23f92023-09-15T14:28:49ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-04-013331473148110.1080/09546634.2020.18326491832649Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured surveyLisa Schots0Lynda Grine1Rani Soenen2Jo Lambert3Department of Dermatology, Ghent University HospitalDepartment of Dermatology, Ghent University HospitalDepartment of Dermatology, Ghent University HospitalDepartment of Dermatology, Ghent University HospitalBackground Therapeutic drug monitoring (TDM) may lead to more rational use of biologics. Still, TDM is largely underexplored in psoriasis. Little is known about the dosing behavior of biologics by dermatologists, and their attitude toward TDM. Objective Exploration of the awareness and need for the concept of TDM in psoriasis amongst (inter)national dermatologists. Method A survey was distributed at the Belgian Dermatology Days 2019 and Skin Inflammation & Psoriasis International Network (SPIN) Congress 2019. Next, an online survey version was launched amongst the SPIN Scientific Committee members. We collected physician’s characteristics, prescription behavior of biologics, data regarding clinical response to biologics and attitude toward TDM. Results A total of 107 surveys were included for analysis. Most dermatologists were Belgium-based (54.2%), others from European (23.4%) or non-European countries (19.6%). Seventy percent performed either dose increase (64.8%), time interval shortening (74.6%), dose lowering (16.9%) or time interval extension (33.8%). The majority who performed dose adaptations acknowledged the need for TDM. Conclusion This study showed most dermatologists perform dose adaptations empirically. The need for TDM was indicated by the majority, implying the need for effective communication regarding availability, utility and implementation of TDM assays in daily dermatology practice.http://dx.doi.org/10.1080/09546634.2020.1832649biologicsdrug concentrationpsoriasisquestionnairetherapeutic drug monitoring |
| spellingShingle | Lisa Schots Lynda Grine Rani Soenen Jo Lambert Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey Journal of Dermatological Treatment biologics drug concentration psoriasis questionnaire therapeutic drug monitoring |
| title | Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey |
| title_full | Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey |
| title_fullStr | Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey |
| title_full_unstemmed | Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey |
| title_short | Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey |
| title_sort | dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis results of a structured survey |
| topic | biologics drug concentration psoriasis questionnaire therapeutic drug monitoring |
| url | http://dx.doi.org/10.1080/09546634.2020.1832649 |
| work_keys_str_mv | AT lisaschots dermatologistsonthemedicalneedfortherapeuticdrugmonitoringofbiologicsinpsoriasisresultsofastructuredsurvey AT lyndagrine dermatologistsonthemedicalneedfortherapeuticdrugmonitoringofbiologicsinpsoriasisresultsofastructuredsurvey AT ranisoenen dermatologistsonthemedicalneedfortherapeuticdrugmonitoringofbiologicsinpsoriasisresultsofastructuredsurvey AT jolambert dermatologistsonthemedicalneedfortherapeuticdrugmonitoringofbiologicsinpsoriasisresultsofastructuredsurvey |